Open data
|
Deployed on AWS
Therapeutically Applicable Research to Generate Effective Treatments (TARGET) is the collaborative effort of a large, diverse consortium of extramural and NCI investigators. The goal of the effort is to accelerate molecular discoveries that drive the initiation and progression of hard-to-treat childhood cancers and facilitate rapid translation of those findings into the clinic.
TARGET projects provide comprehensive molecular characterization to determine the genetic changes that drive the initiation and progression of childhood cancers.The dataset contains open Clinical Supplement, Biospecimen Supplement, RNA-Seq Gene Expression Quantification, miRNA-Seq Isoform Expression Quantification, miRNA-Seq miRNA Expression Quantification data from Genomic Data Commons (GDC), and open data from GDC Legacy Archive.
Overview
Therapeutically Applicable Research to Generate Effective Treatments (TARGET) is the collaborative effort of a large, diverse consortium of extramural and NCI investigators. The goal of the effort is to accelerate molecular discoveries that drive the initiation and progression of hard-to-treat childhood cancers and facilitate rapid translation of those findings into the clinic. TARGET projects provide comprehensive molecular characterization to determine the genetic changes that drive the initiation and progression of childhood cancers.The dataset contains open Clinical Supplement, Biospecimen Supplement, RNA-Seq Gene Expression Quantification, miRNA-Seq Isoform Expression Quantification, miRNA-Seq miRNA Expression Quantification data from Genomic Data Commons (GDC), and open data from GDC Legacy Archive.
Features and programs
Open Data Sponsorship Program
This dataset is part of the Open Data Sponsorship Program, an AWS program that covers the cost of storage for publicly available high-value cloud-optimized datasets.
Pricing
This is a publicly available data set. No subscription is required.
Legal
Content disclaimer
Vendors are responsible for their product descriptions and other product content. AWS does not warrant that vendors' product descriptions or other product content are accurate, complete, reliable, current, or error-free.
Delivery details
AWS Data Exchange (ADX)
AWS Data Exchange is a service that helps AWS easily share and manage data entitlements from other organizations at scale.
Open data resources
Available with or without an AWS account.
- How to use
- To access these resources, reference the Amazon Resource Name (ARN) using the AWS Command Line Interface (CLI). Learn more
- Description
- Clinical Supplement, Biospecimen Supplement, RNA-Seq Gene Expression Quantification, miRNA-Seq Isoform Expression Quantification, miRNA-Seq miRNA Expression Quantification, GDC Legacy Archive
- Resource type
- S3 bucket
- Amazon Resource Name (ARN)
- arn:aws:s3:::gdc-target-phs000218-2-open
- AWS region
- us-east-1
- AWS CLI access (No AWS account required)
- aws s3 ls --no-sign-request s3://gdc-target-phs000218-2-open/
Resources
Vendor resources
Support
Contact
How to cite
Therapeutically Applicable Research to Generate Effective Treatments (TARGET) was accessed on DATE from https://registry.opendata.aws/target .
License
NIH Genomic Data Sharing Policy: https://gdc.cancer.gov/access-data/data-access-policies
Similar products
The global Car T-cell Therapy Market size was valued at USD 6.31 billion in 2024, with an estimation of USD 8.21 billion in 2025, and is predicted to reach USD 30.48 billion by 2030 with a CAGR of 30.0% from 2025-2030. The sector is witnessing robust growth driven by the rising incidence of cancer, particularly hematological malignancies, and the global shift toward precision medicine.
The Pain Management Devices Market represents a vital sector in healthcare innovation projected to expand from USD 7.57 billion in 2025 to USD 12.07 billion by 2030 at a compound annual growth rate of 9.78 percent. This growth is propelled by the rising incidence of chronic diseases an aging global population and advancements in artificial intelligence integrated therapies.
Leading Digital Care Coordination Platform - Design care pathways for each condition and procedure, effectively monitor your patients' rehabilitation and recovery, and improve outcomes while reducing variation and costs.
Aggregating critical information to accelerate drug discovery for the molecular modeling and simulation community.
A community-driven data repository and curation service for molecular structures, models, therapeutics, and
simulations related to computational research related to therapeutic opportunities for COVID-19
(caused by the SARS-CoV-2 coronavirus).
The global Leukemia Therapeutics Market is expected to reach $29 billion by 2030, exhibiting a CAGR of 9% from 2024 to 2030. The substantial growth is attributed to the emergence of innovative treatments like bone marrow transplants and menine inhibition in cancer therapeutics. These advancements not only enhance patient outcomes but also hold the potential to positively impact the healthcare sector, driving further market expansion.
The Exosome Research Market, valued at USD 222.4 million in 2024, is projected to reach USD 606.6 million by 2030, with a CAGR of 18.2%. Driven by chronic disease prevalence, healthcare spending, and academic-industry collaborations, innovations in microfluidics and nanotechnology overcome high costs, with strong growth in North America, Asia-Pacific, and Europe.
The designer phages market, valued at USD 1.57 billion in 2024, is projected to reach USD 2.49 billion by 2030, with a CAGR of 8.0%. Driven by healthcare spending, infectious disease prevalence, and agricultural applications, the market faces regulatory challenges but benefits from innovations in phage display technology, with strong growth in North America, Europe, and Asia-Pacific.